Zacks Investment ResearchWed, 17 Jun 2026 15:21:15 GMTOTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for ReviewOTLK-3.81%
BenzingaWed, 17 Jun 2026 12:39:38 GMTOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth TimeOTLK-3.81%
Seeking AlphaSat, 06 Jun 2026 12:55:23 GMTOutlook Therapeutics: Potential Catalysts Offering An Arbitrage OpportunityOTLK-3.81%
BenzingaTue, 26 May 2026 13:16:09 GMTOutlook Shares Jump Following FDA Appeal Decision For LYTENAVAOTLK-3.81%
Zacks Investment ResearchFri, 15 May 2026 22:25:12 GMTOncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue EstimatesOTLK-3.81%
